Fulgent Genetics to Announce Third Quarter 2021 Financial Results on Tuesday November 9, 2021

Rhea-AI Summary

Fulgent Genetics (NASDAQ: FLGT) will release its third quarter 2021 financial results on November 9, 2021, after market close. The company specializes in genetic testing for oncology, infectious diseases, and reproductive health. A conference call hosted by key executives will take place at 4:30 PM ET to discuss results and answer questions. Investors can access the call via audio webcast or by dialing in. Fulgent Genetics combines NGS technology with an extensive test menu, providing a comprehensive suite of services tailored to client needs.

Positive

• Fulgent's proprietary technology platform provides a flexible test menu.
• The company maintains high accuracy and competitive turnaround times.
• Continual expansion of its proprietary genetic reference library.

Negative

• None.

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its third quarter 2021 financial results after the market closes on Tuesday November 9, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chief Medical Officer Dr. Larry Weiss will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (800) 367-2403 using the confirmation code 3277675. An audio replay will be available in the Investors section of the company’s website.

About Fulgent Genetics

Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005128/en/

Investor Relations Contact:

The Blueshirt Group

Nicole Borsje, 415-217-2633; nicole@blueshirtgroup.com

Source: Fulgent Genetics, Inc.

FAQ

When will Fulgent Genetics announce its Q3 2021 financial results?

Fulgent Genetics will announce its Q3 2021 financial results on November 9, 2021.

What time is the Fulgent Genetics conference call?

The Fulgent Genetics conference call will be held at 4:30 PM ET on November 9, 2021.

How can I access the Fulgent Genetics conference call?

The conference call can be accessed via audio webcast on the company's website or by dialing (800) 367-2403 with the confirmation code 3277675.

What is the focus of Fulgent Genetics?

Fulgent Genetics focuses on genetic testing in oncology, infectious diseases, and reproductive health.

What technology does Fulgent Genetics use for testing?

Fulgent Genetics utilizes next generation sequencing (NGS) technology combined with its proprietary platform for genetic testing.